CHANGES IN GLYCOSYLATED PROTEINS IN TYPE-2 DIABETIC PATIENTS WITH AND WITHOUT COMPLICATIONS

Authors

  • Anjuman Gul
  • M. Ataur Rahman
  • Anila Jaleel

Abstract

Background: Diabetes mellitus constitutes one of the most important problems in developing anddeveloped countries. Increased glycosylation of various proteins in diabetic patients has beenreported by many authors. The present study describes the changes in protein glycosylation indiabetic patients with and without diabetic complication. Methods: The study included onehundred and three subjects. Among them 21 were type 2 diabetic patients without any clinicalevidence of chronic diabetic complications, 21 were type 2 diabetic patients with cardiovascularcomplications, 20 were type 2 diabetic patients with cataract, 20 were type 2 diabetic patients withretinopathy and 21 apparently normal, age, sex and weight matched controls. The patients wereselected from Ziauddin Medical University Hospital, Karachi and Jinnah Postgraduate MedicalCentre, Karachi. Results: Fasting plasma glucose was increased in all diabetic patients andcorrelated significantly with glycosylated hemoglobin, glycosylated plasma proteins and serumfructosamine concentrations. There was no significant difference in the levels of fasting plasmaglucose, glycosylated plasma proteins, glycosylated hemoglobin, serum fructosamine, hexosamineor sialic acid between diabetic patients with or without chronic complications. Alpha-1 and alpha-2 globulin fraction were significantly increased in diabetic patients without complications, diabeticpatients with cardiovascular complications and diabetic patients with cataract. Albumin was foundto be decreased in diabetic patients with cataract while gamma globulin was increased in diabeticpatients with cardiovascular complications and diabetic patients with cataract. Conclusions: Inuncomplicated diabetic patients alpha-1 and alpha-2 glycoproteins were increased. In diabeticpatients with cardiovascular complications alpha-1, alpha-2 and gamma globulin were increasedwhile in diabetic patients with cataract alpha-1, alpha-2 and gamma globulin were increased butserum albumin was significantly decreased.Key words: glycosylated hemoglobin, glycosylated plasma protein, serum fructosamine, sialicacid, hexosamine and total serum proteins.

References

Wilson JD, Braunwald E, Isselbacher KJ, Petersdorf RG,

Martin JB, Facuci AS, et al. Harrison’s “Principles of Internal

Medicine”.12th Edition, New York: McGraw-Hill; 1991. vol:

: 1739-1759.

Alberti KGMM, Zimmet PZ. Defination, diagnosis and

classification of diabetes mellitus and its complication.

Provisional report of WHO consultations. Diabetic Med. 1998;

:539-53.

Shera S. Prevalence and prevention. Diabetes Digest 1998;12:

-8.

Ahmed N. Glycation and diabetic complications. J Pak Med

Assoc 1991;41:171-4.

Brownlee M, Vlassara H, Cerami A. Advanced glycosylation

end products in tissue and the biochemical basis of

complications. New Engl J Med 1998;318:1315-21.

Mandarino LJ. Current hypothesis for the biochemical basis of

diabetic retinopathy. Diabetes Care 1992;15: 1892-1900.

Singleton JR, Smith AG, Russell JW, Feldman EL.

Microvascular Complications of Impaired Glucose Tolerance.

Diabetes. 2003;52: 2867-73.

DCCT (diabetes control and complications trial research

group). The effect of intensive treatment of diabetes on the

development and progression of long-term complications of

insulin-dependent diabetes mellitus. N Engl J Med

;329:977-9.

Forbes JM, Yee LTL, Thallas V, Lassila M, Candido R, Dahm

KAJ, et al. Advanced Glycation End Product Interventions

Reduce Diabetes-Accelerated Atherosclerosis. Diabetes 2004;

: 1813-23.

Brownlee M. Biochemistry and Molecular Cell Biology of

diabetic complications. Nature. 2001; 414: 813-20.

Spiro RG. Glycoproteins: Structure, Metabolism and Biology.

N Engl J Med. 1963; 269: 616-21.

Khan IA, Rahman MA. Variation of saccharoid fraction in

diabetes mellitus. Nature 1967; 215: 979-80.

Kennedy L, Mehl TD, Elder E, Varghese M, Merimee Tj.

Nonenzymatic glycosylation of serum and plasma proteins.

Diabetes. 1982;31:52-56.

Johnson RN, Metcalf PA, Baker JR. Fructosamine, a new

approach to the estimation of serum glycosylprotein, an index

of diabetic control. Clin Chim Acta 1982;127:87-95.

Gabir MM, Roumain J, Hanson RL, Bennett PH, Dabelea D,

Knowler WC, et al. The 1997 American Diabetes Association

and 1999 World Health Organization criteria for

hyperglycemia in the diagnosis and prediction of diabetes.

Diabetes Care 2000;23:1108-12.

Cessi C, Pilliego F. The determination of amino sugars in the

presence of amino acids and glucose. Biochem J1960;77:508-

Varley H, Gowenlock AH, Bell M. Biuret method for protein

estimation, in Practical Clinical Biochemistry. 5th edition.

London, William Heinemann Medical Books Ltd. 1980:545-7.

Natelson S. Microtechniques of clinical chemistry for the

routine laboratory. 2nd edition. Charles C. Thomos, Springfield

III, 1961: 378-80.

Ma A, Naughton MA, Cameron DP. Glycosylated plasma

proteins: a simple method for the elimination of interference

by glucose in its estimation. Clin Chim Acta. 1981;115:111-7.

Ralli EP, Barbosa X, Beck EM, Laken B. Serum

electrophoretic patterns in normal and diabetic subjects.

Metabolism. 1957;6:331-8.

Stratton IM, Adler AI, Neil HA, Mathew DR, Manely SE,

Cull CA, et al. Association of glycemia with macrovascular

and microvascular complication of type 2 diabetes (UKPDS

. Brit Med J 2000;321:405-12.

Mclellan AC, Thornalley PJ, Benn J, Sonksen PH. Glyoxalase

system in clinical diabetes mellitus and correlation with

diabetic complications. Clin Sci 1994;87:21-29.

Rahman MA, Zafar G, Shera AS. Changes in glycosylated

proteins in log-term complications of diabetes mellitus.

Biomed and Pharmacother 1990; 44: 229-34.

Odetti P, Garibaldi S, Noberasco G, Aragno I, Valentini S,

Traverso N, et al. Levels of carbonyl groups in plasma proteins

of type 2 diabetes mellitus subjects. Acta Diabetol

;36:179-83.

J Ayub Med Coll Abbottabad 2005;17(3)

Mandarino LJ. Current hypothesis for the biochemical basis of

diabetic retinopathy. Diabetes Care. 1992; 15: 1892-1900.

Skeie S, Thue G, Sandberg S. Interpretation of hemoglobin

A1C (HbA1C) values among diabetic patients: Implication for

quality specifications for HbA1C. Clincal Chemistry. 2001; 47:

-1217.

Malik M, Gill GV, Pugh RN, Bakir A, Hossain M. Can plasma

fructosamine substitute for glycated haemoglobin (HbA1C)

estimation in the assessment of diabetic control? Trop Doct.

; 30: 74-6.

Henricsson M, Gottsater A, JeppssonJO, Fernlund P,

Sundkvist G. The frequency and severity of retinopathy are

related to HbA1C values after, but not at, the diagnosis of

NIDDM. J Intern Med. 1998; 244: 149-54.

Lis H, Sharon N. Protein glycosylation. Structural and

functional aspects. Eur J Biochem. 1993; 218: 1-27.

Yarema KJ, Bertozzi CR. Characterizing glycosylation

pathway. Genome Biology. 2001; 2(5): 1-10.

Matie L. Plasma protein glycosylation and its alteration in

disease. Rom J Intern Med. 1997; 35: 3-11.

Opdenakker G, Rudd PM, Ponting CP, Dwek RA. Concepts

and principles of glycobiology . FASEB J 1993; 7: 1330-7.

Davis BJ. Synthesis of glycoproteins. Chem Rev, 2002; 102:

-601.

Frankl WS. Glycoproteins in diabetes mellitus and

atherosclerosis. Am J Med Sci. 1964; 248: 588-94.

Berkman J, Rifkin H, Ross G. The serum polysaccharides in

diabetic patients with and without degenerative vascular

disease. J Clin Invest. 1953; 32: 415-21.